Thymosin Alpha-1 Research Guide: Peptide Overview

By /

For laboratory research use only.

Thymosin alpha-1 (Tα1, thymalfasin in some pharmaceutical contexts) is an acetylated thymic peptide fragment studied as an immunomodulatory research tool. It must be kept distinct from thymosin beta-4 / TB-500, which is a different sequence and research story.

Identity

Thymosin alpha-1 is historically associated with thymic hormone research and synthetic/recombinant pharmaceutical development in some regions. Family resemblance in the word “thymosin” is a known confusion source. Sequence identity documents should be preferred over the overlapping family name.

Evidence landscape

Recent evidence-landscape and systematic-review papers examine thymosin alpha-1 as an immunomodulatory adjunct in cancer chemotherapy settings and summarize efficacy/safety signals from aggregated clinical literature (Tα1 immunomodulatory adjunct evidence landscape; Tα1 plus chemotherapy systematic review). A separate review assesses thymosin-α1 in chronic hepatitis B (Tα1 in chronic hepatitis B). Those corpora are medical-evidence discussions attached to defined pharmaceutical uses in the cited papers; they do not automatically describe every research-catalog lot,

Alpha-1 versus beta-4

Thymosin beta-4 is an actin-binding protein; TB-500 is a fragment-style research name in that lineage. Immune-model papers that say only “thymosin” without alpha/beta clarity are hard to map onto a catalog shelf. Write “thymosin alpha-1” in full when that is the material used.

Limits

Immunomodulation findings are study-dependent. Cite papers that actually used alpha-1. Do not recycle beta-4 / TB-500 results under an alpha-1 label.

Sources

Shopping Cart
Scroll to Top